Evidence map›Paper›PMID 25155586›Full record

ArticleAntimicrobial agents and chemotherapy2014

Plasmodium falciparum and Plasmodium vivax genotypes and efficacy of intermittent preventive treatment in Papua New Guinea.

Celine Barnadas, Nicolas Senn, Jonah Iga, Lincoln Timinao, Sarah Javati, Elisheba Malau, Patricia Rarau, John C Reeder, Peter Siba, Harin Karunajeewa and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Celine BarnadasVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea Infection and Immunity Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia Department of Medical Biology, University of Melbourne, Parkville, Australia barnadas@wehi.edu.au ivomueller@fastmail.fm.
Nicolas SennVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea Swiss Tropical and Public Health Institute, Basel, Switzerland.
Jonah IgaVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
Lincoln TiminaoVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
Sarah JavatiVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
Elisheba MalauVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea Infection and Immunity Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia.
Patricia RarauVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
John C ReederBurnet Institute, Melbourne, Australia.
Peter SibaVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
Harin KarunajeewaInfection and Immunity Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia Department of Medical Biology, University of Melbourne, Parkville, Australia.
Peter A ZimmermanCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA.
Timothy M DavisSchool of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
Ivo MuellerInfection and Immunity Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia Department of Medical Biology, University of Melbourne, Parkville, Australia Centre de Recerca en Salut Internacional de Barcelona, Barcelona, Spain barnadas@wehi.edu.au ivomueller@fastmail.fm.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intermittent preventive treatment of infants (IPTi) reduces early childhood malaria-related morbidity. While genotypic drug resistance markers have proven useful in predicting the efficacy of antimalarial drugs in case management, there are few equivalent data relating to their protective efficacy when used as IPTi. The present data from an IPTi trial in Papua New Guinea demonstrate how these markers can predict protective efficacy of IPTi for both Plasmodium falciparum and Plasmodium vivax.

Indexed as

AntimalarialsATP-Binding Cassette, Sub-Family C ProteinsDihydropteroate SynthaseDrug CombinationsDrug ResistanceGenetic MarkersGenotypeHumansInfantMalaria, FalciparumMalaria, VivaxMembrane Transport ProteinsPapua New GuineaPlasmodium falciparumPlasmodium vivaxProtozoan ProteinsAntimalarialsATP-Binding Cassette, Sub-Family C ProteinsDihydropteroate SynthaseDrug CombinationsGenetic MarkersMdr1 protein, Plasmodium falciparumMembrane Transport ProteinsPfCRT protein, Plasmodium falciparumProtozoan ProteinsTetrahydrofolate Dehydrogenase

Identifiers

PMID25155586
PMCPMC4249390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.